NO20030896L - Nye dipeptidyl-peptidase IV-inhibitorer og deres anvendelse som anti-kreftmidler - Google Patents

Nye dipeptidyl-peptidase IV-inhibitorer og deres anvendelse som anti-kreftmidler

Info

Publication number
NO20030896L
NO20030896L NO20030896A NO20030896A NO20030896L NO 20030896 L NO20030896 L NO 20030896L NO 20030896 A NO20030896 A NO 20030896A NO 20030896 A NO20030896 A NO 20030896A NO 20030896 L NO20030896 L NO 20030896L
Authority
NO
Norway
Prior art keywords
inhibitors
cancer agents
dipeptidyl peptidase
dpiv
pharmaceutically acceptable
Prior art date
Application number
NO20030896A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030896D0 (no
Inventor
Hans-Ulrich Demuth
Torsten Hoffmann
Stephan Von Hoersten
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10150203A external-priority patent/DE10150203A1/de
Priority claimed from DE10154689A external-priority patent/DE10154689A1/de
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of NO20030896D0 publication Critical patent/NO20030896D0/no
Publication of NO20030896L publication Critical patent/NO20030896L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
NO20030896A 2001-06-27 2003-02-26 Nye dipeptidyl-peptidase IV-inhibitorer og deres anvendelse som anti-kreftmidler NO20030896L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01114796 2001-06-27
DE10150203A DE10150203A1 (de) 2001-10-12 2001-10-12 Peptidylketone als Inhibitoren der DPIV
DE10154689A DE10154689A1 (de) 2001-11-09 2001-11-09 Substituierte Aminoketonverbindungen
US36090902P 2002-02-28 2002-02-28
PCT/EP2002/007129 WO2003002595A2 (fr) 2001-06-27 2002-06-27 Nouveaux inhibiteurs de dipeptidylpeptidase iv et leurs utilisations en tant qu'agents anti-cancereux

Publications (2)

Publication Number Publication Date
NO20030896D0 NO20030896D0 (no) 2003-02-26
NO20030896L true NO20030896L (no) 2003-04-16

Family

ID=27438020

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20030896A NO20030896L (no) 2001-06-27 2003-02-26 Nye dipeptidyl-peptidase IV-inhibitorer og deres anvendelse som anti-kreftmidler
NO20030895A NO20030895D0 (no) 2001-06-27 2003-02-26 Ny anvendelse av dipeptidyl peptidase IV inhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20030895A NO20030895D0 (no) 2001-06-27 2003-02-26 Ny anvendelse av dipeptidyl peptidase IV inhibitorer

Country Status (9)

Country Link
EP (2) EP1399470A2 (fr)
JP (2) JP2004521149A (fr)
CN (1) CN1321682C (fr)
AT (1) ATE385238T1 (fr)
AU (2) AU2002328306B8 (fr)
CA (2) CA2418543A1 (fr)
DE (1) DE60224879D1 (fr)
NO (2) NO20030896L (fr)
WO (3) WO2003072556A1 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374181T1 (de) 2001-06-27 2007-10-15 Smithkline Beecham Corp Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
RU2004132719A (ru) 2002-04-08 2005-08-27 Торрент Фармасьютикалз Лтд. (In) Тиазолидин-4-карбонитрилы и их аналоги, применение указанных соединений в качестве ингибиторов дипептидилпептидаз
JP4887139B2 (ja) 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
EP1622870A2 (fr) * 2003-05-05 2006-02-08 Prosidion Ltd. Inhibiteurs de la dp iv a base de glutaminyle
DK1620082T3 (da) 2003-05-05 2010-08-16 Probiodrug Ag Medicinsk anvendelse af inhibitorer af glutaminyl- og glutamatcyclaser til behandling af Alzheimers sygdom og Downs syndrom
EP1620091B1 (fr) 2003-05-05 2010-03-31 Probiodrug AG Inhibiteurs de glutaminyl-cyclase
DK2206496T3 (da) 2003-05-05 2014-12-15 Probiodrug Ag Screening af inhibitorer af pyroglutaminsyredannelse i amyloid beta-peptid
EP1631680A2 (fr) * 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4)
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
BRPI0413452A (pt) 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP5707014B2 (ja) 2003-10-15 2015-04-22 プロビオドルグ エージー グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102134231B (zh) 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
WO2005116029A1 (fr) * 2004-05-18 2005-12-08 Merck & Co., Inc. Derives de la cyclohexylalanine utilises comme inhibiteurs de la dipeptidyl peptidase-iv pour le traitement ou la prevention des diabetes
EP1753730A1 (fr) 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
WO2006019965A2 (fr) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Inhibiteurs de la dipeptidyl peptidase
EP2805953B1 (fr) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Inhibiteurs de peptidase dipeptidyl
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
JP2011201923A (ja) * 2005-07-01 2011-10-13 Snow Brand Milk Products Co Ltd ジペプチジルペプチダーゼｉｖ阻害剤
EP1760076A1 (fr) * 2005-09-02 2007-03-07 Ferring B.V. Inhibiteur de FAP
CA2622472C (fr) 2005-09-14 2013-11-19 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
AU2006297130B2 (en) * 2005-09-30 2009-12-24 Novartis Ag DPP IV inhibitor for use in the treatment of autoimmune diseases and graft rejection
JP2009509552A (ja) 2005-10-04 2009-03-12 イニメックス ファーマシューティカルズ インコーポレイテッド 先天免疫を調節することによる感染の処置および予防を含む、免疫関連疾患障害の処置および予防のための新規ペプチド
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
JP5374058B2 (ja) * 2008-03-12 2013-12-25 株式会社 資生堂 グルタミン酸誘導体、不全角化抑制剤、毛穴縮小剤、肌荒れ防止・改善剤及び皮膚外用組成物
EP2146210A1 (fr) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011029920A1 (fr) 2009-09-11 2011-03-17 Probiodrug Ag Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
BR112012022478B1 (pt) 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
EP2418196A1 (fr) * 2010-07-29 2012-02-15 IMTM GmbH Inhibiteurs doubles d'alanyl-aminopeptidase et de dipeptidylpeptidase IV
PE20131371A1 (es) 2010-09-22 2013-11-25 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
EP2686313B1 (fr) 2011-03-16 2016-02-03 Probiodrug AG Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
WO2012135570A1 (fr) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (fr) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
ES2785094T3 (es) * 2011-11-21 2020-10-05 Emmaus Medical Inc Métodos y composiciones para el tratamiento de la diabetes y los síntomas relacionados
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
CA2922239A1 (fr) * 2013-09-23 2015-03-26 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Tripeptides anti-inflammatoires
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN105343068A (zh) * 2015-12-14 2016-02-24 上海壹志医药科技有限公司 苦参碱的药物用途
TW201840582A (zh) * 2017-03-21 2018-11-16 日商富士軟片股份有限公司 肽化合物及其製造方法、篩選用組成物、以及肽化合物的選擇方法
MX2019011867A (es) 2017-04-03 2020-01-09 Coherus Biosciences Inc Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva.
CN107158006A (zh) * 2017-05-31 2017-09-15 上海壹志医药科技有限公司 葫芦素d的药物用途
CN107375302A (zh) * 2017-05-31 2017-11-24 上海壹志医药科技有限公司 葫芦素b的药物用途
CN107007612A (zh) * 2017-05-31 2017-08-04 上海壹志医药科技有限公司 葫芦素c的药物用途
CN107115348A (zh) * 2017-05-31 2017-09-01 上海壹志医药科技有限公司 葫芦素e的药物用途
EP3461819B1 (fr) 2017-09-29 2020-05-27 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase
JP7056702B2 (ja) * 2020-09-15 2022-04-19 井関農機株式会社 脱穀装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD296075A5 (de) * 1989-08-07 1991-11-21 Martin-Luther-Universitaet Halle-Wittenberg,De Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
NZ508642A (en) * 1998-06-05 2003-10-31 Point Therapeutics Inc Cyclic boroproline compounds
DE19826972A1 (de) * 1998-06-18 1999-12-23 Univ Magdeburg Tech Verwendung von Enzyminhibitoren und pharmazeutische Zubereitung zur Therapie von dermatologischen Erkrankungen mit follikulären und epidermalen Hyperkeratosen und einer verstärkten Keratinozytenproliferation
WO2000010549A1 (fr) * 1998-08-21 2000-03-02 Point Therapeutics, Inc. Regulation de l'activite de substrat
WO2001034594A1 (fr) * 1999-11-12 2001-05-17 Guilford Pharmaceuticals, Inc. Inhibiteurs de la dipeptidyl peptidase iv; methodes de fabrication et d'utilisation desdits inhibiteurs
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
DE10025464A1 (de) * 2000-05-23 2001-12-06 Inst Medizintechnologie Magdeb Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
EP1315829B1 (fr) * 2000-09-09 2010-07-28 The Research Foundation Of State University Of New York Methodes et compositions d'isolation de cellules cancereuses metastatiques, et utilisation correspondante lors de la mesure du potentiel metastatique d'un cancer

Also Published As

Publication number Publication date
EP1399471A2 (fr) 2004-03-24
NO20030895L (no) 2003-02-26
WO2003002595A2 (fr) 2003-01-09
AU2002328306B8 (en) 2008-02-21
JP2004521149A (ja) 2004-07-15
ATE385238T1 (de) 2008-02-15
NO20030895D0 (no) 2003-02-26
WO2003072556A1 (fr) 2003-09-04
CN1321682C (zh) 2007-06-20
AU2002321135B2 (en) 2007-11-08
DE60224879D1 (de) 2008-03-20
AU2002328306B2 (en) 2007-09-06
CN1464881A (zh) 2003-12-31
EP1399471B1 (fr) 2008-01-30
WO2003002596A2 (fr) 2003-01-09
JP2004534836A (ja) 2004-11-18
WO2003002596A3 (fr) 2003-07-31
CA2418543A1 (fr) 2003-01-09
EP1399470A2 (fr) 2004-03-24
CA2424645A1 (fr) 2003-01-09
WO2003002595A3 (fr) 2003-05-08
NO20030896D0 (no) 2003-02-26

Similar Documents

Publication Publication Date Title
NO20030896D0 (no) Nye dipeptidyl-peptidase IV-inhibitorer og deres anvendelse som anti-kreftmidler
DK1480961T3 (da) Glutaminylbaserede DPIV-inhibitorer
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
MXPA03011907A (es) Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
GEP20094679B (en) Dipeptidyl peptidase inhibitors
YU84603A (sh) Novi inhibitori tirozin kinaze
WO2003002530A3 (fr) Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase
CA2473070A1 (fr) Composes de proline utilises en tant qu'inhibiteurs de la serine protease ns3 dans le traitement d'une infection par le virus de l'hepatite c
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
WO2005033099A3 (fr) Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant
HU0302788D0 (en) New compounds
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
WO2003002553A3 (fr) Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase
CY1108146T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ
TW200509892A (en) Novel aminobenzophenone compounds
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
TW200510311A (en) CCr8 inhibitors
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
TW200612940A (en) Substituted tetrahydroisoquinolines as mmp inhibitors, process for their preparation and their use as medicament
UA86051C2 (en) Substituted quinoline compounds
GB0223223D0 (en) Organic compounds
ATE355287T1 (de) 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten
RS20060049A (en) Novel n-substituted indolyl-3-glycoxylic acid amides, use thereof as a medicament and method for the production thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application